ProCE Banner Activity

Overview of Risk Assessment and Biomarker Testing to Inform Treatment in HER2-Negative Early Breast Cancer

Slideset Download
This slideset offers an overview of current risk assessment and biomarker testing used to inform treatment decisions and predict treatment response and prognosis in patients with HER2-negative early breast cancer.

Released: April 06, 2022

Expiration: April 05, 2023

No longer available for credit.

Share

Faculty

Yara Abdou

Yara Abdou, MD

Assistant Professor
Division of Medical Oncology
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Lilly

Merck Sharp & Dohme Corp.

Partners

Smart Patients

ProCE Banner

Faculty Disclosure

Primary Author

Yara Abdou, MD

Assistant Professor
Division of Medical Oncology
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Yara Abdou, MD, has disclosed that she has received consulting fees from Exact Sciences.